Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

25411 BCR/ABL-1 RNA-Qual Diagnostic (BADX)

BCR/ABL-1 RNA-Qual Diagnostic (BADX)
Test Code: BCRADSO
Synonyms/Keywords
Philadelphia chromosome Ph bone marrow/blood
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
BCR-ABL1
BCR ABL
BCR/ABL
B lymphoblastic leukemia (B-ALL)
Chronic myelogenous leukemia (CML)
Chronic myeloid leukemia
T lymphoblastic leukemia (T-ALL)
t(9;22)
Test Components

​This test is only qualitative and should not be used for routine monitoring (ie, quantitative mRNA level).

Monitoring of most patients with chronic myeloid leukemia (CML) should be performed using BCRAB / BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML), Varies.

Monitoring of patients known to carry a p190 fusion should be performed using BA190 / BCR/ABL, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.

Useful For

​DIAGNOSTIC workup of patients with a high probability of BCR-ABL1-positive hematopoietic neoplasms, predominantly chronic myelogenous leukemia and acute lymphoblastic leukemia.

Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repea​​t)
​Submit only 1 of the following specimens:  ​ ​ ​ ​ ​
​Whole Blood ​Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​10 mL ​8 mL ​
​Bone Marrow ​​Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​4 mL ​2 mL ​
Collection Processing Instructions

Refrigerate specimens must arrive within 5 days of collection, and ambient specimens must arrive with 3 days (72 hours) of collection. Collect and package specimens as close to shipping time as possible.

Necessary Information:

The following information is required:

1. Pertinent clinical history including if the patient has a diagnosis of chronic myelogenous leukemia or other BCR/ABL1-positive neoplasm

2. Date of collection

3. Specimen source (blood or bone marrow)

Specimen Stability Information
Specimen Type Temperature Time​​
Varies ​ Refrigerated (preferred) 5 days
​Ambient 72 hours
Rejection Criteria
Gross hemolysis or moderately to severely clotted
Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available Methodology/Instrumen​​tation
​Mayo Clinic Laboratories ​Monday through Saturday ​5 to 10 days Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Multiplex PCR
Reference Lab
Mayo Clinic Laboratories
Reference Range Information
Interpretive Report
Interpretation

An interpretive report will be provided.

When positive, the test identifies the specific mRNA fusion variant present to guide selection of an appropriate monitoring assay.

Monitoring is available for common p210 or p190 fusion variant detected.

-Common fusion variants detected: e13-a2 or e14-a2 (p210), e1-a2 (p190), and e6-a2 (p205*)

-Rare fusion variants detected: e13-a3 (p210), e14-a3 (p210), e1-a3 (p190), e19-a2 (p230)

-Potential rare fusions detected: e12-a3, e19-a3

*This is formerly observed as the e6-a2 (p185) fusion form.

Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​81206 ​ ​1 ​BCR/ABL 1 (t9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative ​
​81207 ​ ​1 ​BCR/ABL 1 (t9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative ​
​81208 ​ ​1 ​BCR/ABL 1 (t9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative ​
Synonyms/Keywords
Philadelphia chromosome Ph bone marrow/blood
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
BCR-ABL1
BCR ABL
BCR/ABL
B lymphoblastic leukemia (B-ALL)
Chronic myelogenous leukemia (CML)
Chronic myeloid leukemia
T lymphoblastic leukemia (T-ALL)
t(9;22)
Test Components

​This test is only qualitative and should not be used for routine monitoring (ie, quantitative mRNA level).

Monitoring of most patients with chronic myeloid leukemia (CML) should be performed using BCRAB / BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML), Varies.

Monitoring of patients known to carry a p190 fusion should be performed using BA190 / BCR/ABL, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.

Ordering Applications
Ordering Application Description
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repea​​t)
​Submit only 1 of the following specimens:  ​ ​ ​ ​ ​
​Whole Blood ​Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​10 mL ​8 mL ​
​Bone Marrow ​​Lavender Top Tube (LTT) ​ACD Yellow Top Tube ​4 mL ​2 mL ​
Collection Processing

Refrigerate specimens must arrive within 5 days of collection, and ambient specimens must arrive with 3 days (72 hours) of collection. Collect and package specimens as close to shipping time as possible.

Necessary Information:

The following information is required:

1. Pertinent clinical history including if the patient has a diagnosis of chronic myelogenous leukemia or other BCR/ABL1-positive neoplasm

2. Date of collection

3. Specimen source (blood or bone marrow)

Specimen Stability Information
Specimen Type Temperature Time​​
Varies ​ Refrigerated (preferred) 5 days
​Ambient 72 hours
Rejection Criteria
Gross hemolysis or moderately to severely clotted
Useful For

​DIAGNOSTIC workup of patients with a high probability of BCR-ABL1-positive hematopoietic neoplasms, predominantly chronic myelogenous leukemia and acute lymphoblastic leukemia.

Test Components

​This test is only qualitative and should not be used for routine monitoring (ie, quantitative mRNA level).

Monitoring of most patients with chronic myeloid leukemia (CML) should be performed using BCRAB / BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML), Varies.

Monitoring of patients known to carry a p190 fusion should be performed using BA190 / BCR/ABL, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.

Reference Range Information
Interpretive Report
Interpretation

An interpretive report will be provided.

When positive, the test identifies the specific mRNA fusion variant present to guide selection of an appropriate monitoring assay.

Monitoring is available for common p210 or p190 fusion variant detected.

-Common fusion variants detected: e13-a2 or e14-a2 (p210), e1-a2 (p190), and e6-a2 (p205*)

-Rare fusion variants detected: e13-a3 (p210), e14-a3 (p210), e1-a3 (p190), e19-a2 (p230)

-Potential rare fusions detected: e12-a3, e19-a3

*This is formerly observed as the e6-a2 (p185) fusion form.

For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available Methodology/Instrumen​​tation
​Mayo Clinic Laboratories ​Monday through Saturday ​5 to 10 days Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Multiplex PCR
Reference Lab
Mayo Clinic Laboratories
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​81206 ​ ​1 ​BCR/ABL 1 (t9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative ​
​81207 ​ ​1 ​BCR/ABL 1 (t9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative ​
​81208 ​ ​1 ​BCR/ABL 1 (t9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative ​
For most current information refer to the Marshfield Laboratory online reference manual.